{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-393081","form_type":"8-K","ticker":"AVLN","cik":"0001540171","company_name":"Avalyn Pharma Inc.","filed_at":"2026-09-16T20:13:18+00:00","discovered_at":"2026-09-16T20:15:10.391442+00:00","generated_at":"2026-09-16T20:15:16.602487+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Avalyn Pharma appoints former FDA director Robert Meyer to board","bullets":["Appointed Robert Meyer, M.D. as Class II director effective Sept 15, 2026; term expires at 2028 annual meeting.","Meyer is independent under Nasdaq rules; ex-FDA drug evaluation director and Merck VP for global regulatory strategy.","Eligible for $40,000 annual retainer; initial option for 31,182 shares vesting over 3 years plus annual 15,591-share grants.","No arrangements or transactions requiring disclosure; signed standard indemnification agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-393081","json":"https://secwatch.observer/filing/0001193125-26-393081.json","markdown":"https://secwatch.observer/filing/0001193125-26-393081.md","text":"https://secwatch.observer/filing/0001193125-26-393081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540171/000119312526393081/0001193125-26-393081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540171/000119312526393081/ck0001540171-20260915.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-16T20:15:16.602487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}